Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | WNT1 | P04628 | 2/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | CLK3 | P49761 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3798283 | 0.93 | PRMT5 (0.61) | USP30PRMT5ALDH1A1 | |
| SCHEMBL3794527 | 0.89 | PRMT5 (0.61) | USP30PRMT5ALDH1A1 | |
| SCHEMBL3805082 | 0.82 | CTSS (0.58) | PRMT5CTSSMAPK14ALDH1A1TSHR | |
| SCHEMBL3802520 | 0.80 | CTSS (0.50) | CTSSMAPK14ALDH1A1TSHR | |
| SCHEMBL3800578 | 0.80 | TAS1R3 (0.53) | USP30ALDH1A1 | |
| SCHEMBL3800966 | 0.79 | PRMT5 (0.51) | USP30PRMT5ALDH1A1 | |
| SCHEMBL3796001 | 0.77 | HPGDS (0.59) | USP30PRMT5ALDH1A1TSHR | |
| SCHEMBL3797249 | 0.77 | HPGDS (0.59) | USP30PRMT5ALDH1A1TSHR | |
| SCHEMBL3798846 | 0.75 | NPC1 (0.52) | USP30CTSSALDH1A1 | |
| SCHEMBL3798848 | 0.75 | NPC1 (0.52) | USP30CTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709478-B2 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-1362027-B1 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-05-21 | — | — | EP | disclosed |
| US-20040225013-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-6759412-B2 | FOR PRODUCING DRUGS USED FOR THERAPY OF CARDIOVASCULAR DISEASES, STABLE OR UNSTABLE ANGINA PECTORIS, CORONARY HEART DISEASE, PRINZMETAL ANGINA, ACUTE CORONARY SYNDROME, HEART FAILURE, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | disclosed |
| EP-1362027-A2 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-09 | — | — | US | disclosed |
| WO-2002064546-A2 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | VEGFA, NR1H2, EDNRA | USP30 4179/4885PRMT5 235/4885HRH4 46/4885 |
| US-20040225013-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | VEGFA, NR1H2, EDNRA | USP30 4179/4885PRMT5 235/4885HRH4 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.